General
Preferred name
VORINOSTAT
Synonyms
suberoylanilide hydroxamic acid (SAHA) ()
SAHA ()
Zolinza ()
MK0683 ()
suberoylanilide hydroxamic acid ()
Vorinostat (SAHA) ()
SAHA,MK0683, Suberoylanilide hydroxamic acid, Zolinza ()
VorinostatZolinzaSAHASuberoylanilide hydroxamic acidN-hydroxy-N'-phenyl-octane-1,8-diotic acid diamideSKI390WIN64652L-001079038Octanediamide, N-hydroxy-N'-phenyl- ()
SAHA-d5 ()
NSC-748799 ()
MK-0683 ()
NSC-759852 ()
NSC-701852 ()
P&D ID
PD001323
CAS
149647-78-9
1227736-21-1
1132749-48-4
Tags
available
covalent binder
nuisance
drug
obsolete probe
Approved by
FDA
First approval
2006
Drug indication
HIV infection
Cutaneous T-cell lymphoma
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Vorinostat inhibits Class I, II and IV histone deacetylases (our pages for HDACs are available using this link). (GtoPdb)
DESCRIPTION Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID50 values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis[1][4]. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification[7].
PRICE 29
DESCRIPTION inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (Informer Set)
DESCRIPTION Thymidylate synthetase inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Class I and II HDAC inhibitor (Tocriscreen Plus)
DESCRIPTION Vorinostat is a histone deacetylase inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma following prior systemic therapies. (Enamine Bioactive Compounds)
DESCRIPTION Vorinostat (SAHA) is a pan-histone deacetylase (HDAC) inhibitor (IC50=10 nM) with inhibitory activity against HDAC1/2/3/6/7/11. Vorinostat has antitumor activity, induces cell differentiation, blocks the cell cycle and induces apoptosis. (TargetMol Bioactive Compound Library)
Cell lines
694
Organisms
12
Compound Sets
41
A Collection of Useful Nuisance Compounds (CONS) for Interrogation of Bioassay Integrity
AdooQ Bioactive Compound Library
A10979
Axon Medchem Screening Library
3114
Cayman Chemical Bioactives
10009929
22107
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL98
ChEMBL Drugs
CHEMBL98
Concise Guide to Pharmacology 2019/20
6852
Concise Guide to Pharmacology 2021/22
6852
Concise Guide to Pharmacology 2023/24
6852
CovalentInDB
CI000012
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB02546
DrugBank Approved Drugs
DB02546
DrugCentral
4124
DrugCentral Approved Drugs
4124
DrugMAP
DMWMPD4
DrugMAP Approved Drugs
DMWMPD4
Enamine Bioactive Compounds
EBC-11271
Enamine BioReference Compounds
Guide to Pharmacology
6852
Informer Set
56554
LINCS compound set
10282-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL98
MedChem Express Bioactive Compound Library
HY-10221
NCATS Inxight Approved Drugs
58IFB293JI
NIH Approved Oncology Drugs
48426290
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Obsolete Compounds
vorinostat
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Vorinostat-saha
TargetMol Bioactive Compound Library
T1583
The Spectrum Collection
Tocris Bioactive Compound Library
4652
Tocriscreen Plus
4652
Welcome Trust Cancer Drugs
1012
ZINC Tool Compounds
ZINC000001543873
External IDs
58
Properties
(calculated by RDKit )
Molecular Weight
264.15
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
1
Aromatic Ring Count
1
cLogP
2.47
TPSA
78.43
Fraction CSP3
0.43
Chiral centers
0.0
Largest ring
6.0
QED
0.38
Structural alerts
2
historic compounds (Chemical Probes.org)
Obsolete
Nonspecific HDAC inhibition
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
HDAC inhibitor Class I, IIa, IIb, IV
Histone deacetylase 3
Histone deacetylase 1
Histone deacetylase 2
Histone deacetylase 6
HIV
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
Autophagy,HDAC,HPV
Filovirus
HPV
Mitophagy
Compound status
FDA
Target Type
Enzymes
Pathway
chromain histone acetylation
Apoptosis
Autophagy
Chromatin/Epigenetic
DNA Damage/DNA Repair
Microbiology/virology
Anti-infection
Cell Cycle/DNA Damage
Epigenetics
MOA
histone deacetylase inhibitor
HDAC
Inhibitor
HDACs
Apoptosis Inducers
Histone Deacetylase 1 (HDAC1) Inhibitors
Histone Deacetylase 2 (HDAC2) Inhibitors
Histone Deacetylase 6 (HDAC6) Inhibitors
Histone Deacetylase 3 (HDAC3) Inhibitors
"HDACs
Inhibitor"
HDAC inhibitor
Primary Target
Non-selective HDACs
Member status
member
Indication
cutaneous T-cell lymphoma (CTCL)
Therapeutic Class
Anticancer Agents
Nuisance MOA
Nonspecific HDAC inhibition
Targets
Histone deacetylases (HDACs) Human papillomaviruse (HPV)-18
Source data